Some drugs require more than one biomarker test (for instance, both KRAS and EGFR tests are required before the prescription of cetuximab for colorectal cancer), and some biomarker tests are used for more than one drug (for instance, the HER2 test is required before prescription of trastuzumab and lapatinib for breast cancer). This evidence concerns the gene ERBB2 and colorectal cancer.